荷兰心脏注册:不同主动脉瓣假体模型SAVR术后十年无再干预生存比较
基于荷兰心脏注册2007-2018年成人孤立初次SAVR真实世界数据,比较不同机械瓣与生物瓣模型的十年结局。生物瓣11,139例中,Perimount Magna Ease十年生存最高(72.6%),Mitroflow最低(50.7%);无再干预率Perimount Magna最高(99.3%),Mitroflow最低(90.5%)。机械瓣2,123例中,Regent十年生存最高(91.2%),Carbomedics Reduced无再干预率最高(97.1%)。
要点
- 生物瓣模型间十年生存差异明显(50.7%–72.6%),Mitroflow与Freedom Solo较低。
- 生物瓣十年无再干预率90.5%–99.3%,Perimount Magna最高、Mitroflow最低。
- 机械瓣十年生存与无再干预率整体优于生物瓣,但模型间仍有差异。
核心结论
- 荷兰心脏注册数据显示,不同主动脉瓣假体模型SAVR术后十年结局存在差异,生物瓣模型尤为明显。
- 生物瓣十年生存从50.7%到72.6%不等,无再干预率从90.5%到99.3%不等。
研究设计与样本
- 基于荷兰心脏注册的观察性真实世界研究,纳入2007–2018年成人孤立初次SAVR,排除活动性心内膜炎。
- 仅分析植入超过200次的瓣膜模型;生物瓣11,139例,机械瓣2,123例。
- 生存分析采用Cox比例风险模型,无再干预分析采用Fine and Gray模型并以死亡为竞争事件。
主要发现
- 生物瓣中,Perimount Magna Ease十年生存最高(72.6%),Epic为70.0%,Perimount Magna为65.1%,Trifecta为63.1%,Perimount为61.4%,Freedom Solo为51.5%,Mitroflow为50.7%。
- 生物瓣十年无再干预率Perimount Magna最高(99.3%),Perimount Magna Ease为98.2%,Perimount为98.2%,Epic为97.3%,Trifecta为96.8%,Freedom Solo为93.2%,Mitroflow为90.5%。
- 机械瓣中,Regent十年生存最高(91.2%),Open Pivot为89.2%,Slimline为87.5%,HP为87.3%,Carbomedics Reduced为87.0%。
- 机械瓣十年无再干预率Carbomedics Reduced最高(97.1%),Open Pivot为96.1%,Slimline为96.5%,Regent为95.9%,HP为94.9%。
临床怎么用
- 选择主动脉瓣假体模型时可参考不同模型的大样本真实世界十年生存与再干预数据。
- 生物瓣模型间结局差异较大,Mitroflow与Freedom Solo的十年生存及无再干预率相对较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare long-term outcomes across different models of mechanical and biological aortic valve prostheses after surgical aortic valve replacement (SAVR) in the Netherlands. METHODS: Data from the Netherlands Heart Registration on isolated, primary SAVR procedures performed from 2007 to 2018 in adult patients were used, excluding active endocarditis. Ten-year survival and freedom from valve-related reintervention were estimated for models that were implanted >200 times, using Cox proportional hazards models for survival and Fine and Gray's models with death as the competing-event for freedom of reintervention. RESULTS: For 11,139 patients treated with a biological prosthetic aortic valve, ten-year survival was highest for the Perimount Magna Ease (72.6%) and Epic (70.0%), and significantly lower for the Perimount Magna (65.1%), Trifecta (63.1%), Perimount (61.4%), Freedom Solo (51.5%), and Mitroflow (50.7%). Ten-year freedom from reintervention was highest for the Perimount Magna (99.3%), and significantly lower for the Perimount Magna Ease (98.2%), Perimount (98.2%), Epic (97.3%), Trifecta (96.8%), Freedom Solo (93.2%) and Mitroflow (90.5%). For 2,123 patients treated with a mechanical prosthetic aortic valve, ten-year survival was highest for the Regent (91.2%) and not significantly different for the Open Pivot (89.2%), Slimline (87.5%), HP (87.3%) and significantly lower for the Carbomedics Reduced (87.0%). Ten-year freedom from reintervention was highest for the Carbomedics Reduced (97.1%), not significantly different for the Open Pivot (96.1%), Slimline (96.5%), Regent (95.9%), and significantly lower for the HP (94.9%). CONCLUSIONS: Differences in ten-year outcomes after SAVR were observed for the different prosthetic aortic valve models that were used in the Netherlands Heart Registration, especially for biological prosthetic aortic valve models, with survival varying from 50.7% to 72.6% and freedom from reintervention from 90.5% to 99.3%.
引用
- de Beaufort HWL, Roefs MM, Daeter EJ, et al. Ten-year reintervention-free survival after surgical aortic valve replacement for different prosthetic aortic valve models: comparison using real-world data from the Netherlands Heart Registration. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42671119. doi:10.1093/icvts/ivag240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。